Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Regulus Therapeutics Inc.
Type
Public
Industry Biotechnology
Founded September 2007 (by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS))
Headquarters San Diego, California, USA
Key people
Jay Hagan, President and CEO; Dr Timothy Wright, Chief R&D Officer; Dan Chevallard, CFO; Dr Mark Deeg, CMO
Products microRNA therapeutics
Number of employees
65
Website www.regulusrx.com

Regulus Therapeutics Inc. or Regulus (NASDAQ: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.

MicroRNAs are small naturally occurring RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead have evolved to regulate gene expression.

Anti-miR therapeutics inhibit specific microRNA targets. Animal models showed that modulating microRNAs through anti-miRs effectively regulates biological processes and provides therapeutic benefit to cardiac dysfunction, cancer and hepatitis C virus infection. Administration of anti-miR oligonucleotides is possible through local or parenteral injection. The company's lead drug candidate, RG-012, is intended as a treatment for Alport Symdrome in Phase 2 clinical trials.

Regulus has active collaborations with leading academic researchers from over 30 academic research laboratories globally.

Regulus has more than 900 patents and patent applications, 600 of which cover the method of use, chemical modification and administration of oligonucleotides to address specific targets.

Investment goal date:
Dividends reinvested
Regulus Therapeutics Inc. RGLS report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-04
--
--
Q4 2017
2018-02-28
--
--
Q4 2017
2018-02-23
--
--
Q3 2017
2017-11-07
--
--
Q3 2017
2017-11-07
-0.1800
0.0000
Q2 2017
2017-08-01
-0.4100
-0.4100
Q1 2017
2017-05-04
-0.3800
-0.3800
Q4 2016
2017-03-02
-0.3800
-0.3800
Q3 2016
2016-11-01
-0.3700
-0.3700
Q2 2016
2016-08-02
-0.4000
-0.4000
Q1 2016
2016-05-02
-0.4000
-0.4000
Q4 2015
2016-02-22
-0.1400
-0.1400
Q3 2015
2015-11-05
-0.2500
-0.2500
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
116400
BNP PARIBAS ARBITRAGE, SA
341
DOWLING & YAHNKE LLC
11500
GOLDMAN SACHS GROUP INC
127395
LEGAL & GENERAL GROUP PLC
11999
MORGAN STANLEY
62015
RHUMBLINE ADVISERS
55537
SCHWAB CHARLES INVESTMENT MANAGEMENT INC
61781
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
395000
WEDBUSH MORGAN SECURITIES INC
180921
Major Shareholders
Name Relationship
Total Shares
Holding stocks
ISIS PHARMACEUTICALS INC
11.9200% (5173172)
ISIS / RGLS /
CROOKE STANLEY T
16.2500% (7049500)
ISIS / RGLS /
ASTRAZENECA PLC
9.7900% (4250000)
RGLS /
PARSHALL B LYNNE
16.2500% (7049500)
CYTK / ISIS / RGLS /
SANOFI-AVENTIS
11.6500% (5053779)
ALNY / KBIO / REGN / RGLS /
ALNYLAM PHARMACEUTICALS, INC.
11.2800% (4896716)
ALNY / RGLS /
MARAGANORE JOHN
14.1700% (6150500)
AGIO / ALNY / BLUE / RGLS /
PAPADOPOULOS STELIOS
4.0800% (1770677)
BGMD / BIIB / EXEL / RGLS /
RASTETTER WILLIAM H
1.4400% (624625)
FOLETTA MARK G
0.0200% (10000)
AHS / AMBI / DXCM / RGLS /
XANTHOPOULOS KLEANTHIS G
0.0100% (3705)
APRI / RGLS / ZSAN /
Greene Barry E
14.1700% (6150500)
ACOR / ALNY / KPTI / RGLS /
Hagan Joseph P
0.5600% (241297)
OREX / RGLS / ZSAN /
WRIGHT TIMOTHY MICHAEL
0.6300% (274725)
RGLS /
% ()